Antiplatelet therapy for peripheral arterial disease and critical limb ischemia

Guidelines abound, but where are the data?

Amir Azarbal, Leonardo Clavijo, Michael A. Gaglia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.

Original languageEnglish (US)
Pages (from-to)144-156
Number of pages13
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume20
Issue number2
DOIs
StatePublished - Mar 14 2015
Externally publishedYes

Fingerprint

Peripheral Arterial Disease
Ischemia
Extremities
Guidelines
clopidogrel
Dipyridamole
Therapeutics
Aspirin
Prostaglandins
Blood Vessels
Population

Keywords

  • antiplatelet therapy
  • aspirin
  • clopidogrel
  • critical limb ischemia
  • peripheral arterial disease heart disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Antiplatelet therapy for peripheral arterial disease and critical limb ischemia : Guidelines abound, but where are the data? / Azarbal, Amir; Clavijo, Leonardo; Gaglia, Michael A.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 20, No. 2, 14.03.2015, p. 144-156.

Research output: Contribution to journalArticle

@article{40452f38b44d4f7c82f5b5e36473293c,
title = "Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?",
abstract = "Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.",
keywords = "antiplatelet therapy, aspirin, clopidogrel, critical limb ischemia, peripheral arterial disease heart disease",
author = "Amir Azarbal and Leonardo Clavijo and Gaglia, {Michael A.}",
year = "2015",
month = "3",
day = "14",
doi = "10.1177/1074248414545126",
language = "English (US)",
volume = "20",
pages = "144--156",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Antiplatelet therapy for peripheral arterial disease and critical limb ischemia

T2 - Guidelines abound, but where are the data?

AU - Azarbal, Amir

AU - Clavijo, Leonardo

AU - Gaglia, Michael A.

PY - 2015/3/14

Y1 - 2015/3/14

N2 - Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.

AB - Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.

KW - antiplatelet therapy

KW - aspirin

KW - clopidogrel

KW - critical limb ischemia

KW - peripheral arterial disease heart disease

UR - http://www.scopus.com/inward/record.url?scp=84922676567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922676567&partnerID=8YFLogxK

U2 - 10.1177/1074248414545126

DO - 10.1177/1074248414545126

M3 - Article

VL - 20

SP - 144

EP - 156

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 2

ER -